Annexin V associates with the IFN-gamma receptor and regulates IFN-gamma signaling. 2006

Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
Department of Medicine, Division of Infectious Diseases, Faculties of Medicine and Science, University of British Columbia, 2733 Heather Street, Vancouver, BC, Canada.

Many of the biological activities of IFN-gamma are mediated through the IFN-gammaR3-linked Jak-Stat1alpha pathway. However, regulation of IFN-gamma signaling is not fully understood, and not all responses to IFN-gamma are Stat1alpha dependent. To identify novel elements involved in IFN-gamma cell regulation, the cytoplasmic domain of the R2 subunit of the human IFN-gammaR was used as bait in a yeast two-hybrid screen of a human monocyte cDNA library. This identified annexin A5 (AxV) as a putative IFN-gammaR binding protein. The interaction was confirmed in pull-down experiments in which a GST-R2 cytoplasmic domain fusion protein was incubated with macrophage lysates. Furthermore, immunoprecipitation using anti-IFN-gammaR2 Abs showed that AxV interacted with IFN-gammaR2 to form a stable complex following incubation of cells with IFN-gamma. In 293T cells with reduced expression of AxV, brought about by small interfering RNA targeting, activation of Jak2 and Stat1alpha in response to IFN-gamma was enhanced. Inhibition of cell proliferation, a hallmark of the IFN-gamma response, also was potentiated in HeLa cells treated with small interfering RNA directed at AxV. Taken together, these results suggest that through an inducible association with the R2 subunit of the IFN-gammaR, AxV modulates cellular responses to IFN-gamma by modulating signaling through the Jak-Stat1 pathway.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000096743 Interferon gamma Receptor A heterodimeric receptor composed of two subunits IFNGR1 and IFNGR2. Activated IFNGR1 subunit is believed to form a docking site for SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1). IFNGR2 associates with IFNGR1 to form a receptor for the cytokine interferon gamma (IFNG). CD119 Antigen,CDw119 Antigen,IFN-gamma Receptor 1,IFNGR2 Protein,Interferon gamma Receptor 2,Interferon gamma Receptors,Receptor, Interferon gamma,IFN-gammaR,1, IFN-gamma Receptor,Antigen, CD119,Antigen, CDw119,IFN gamma Receptor 1,IFN gammaR,Protein, IFNGR2,Receptor 1, IFN-gamma,Receptors, Interferon gamma,gamma Receptor, Interferon,gamma Receptors, Interferon
D012441 Saccharomyces cerevisiae A species of the genus SACCHAROMYCES, family Saccharomycetaceae, order Saccharomycetales, known as "baker's" or "brewer's" yeast. The dried form is used as a dietary supplement. Baker's Yeast,Brewer's Yeast,Candida robusta,S. cerevisiae,Saccharomyces capensis,Saccharomyces italicus,Saccharomyces oviformis,Saccharomyces uvarum var. melibiosus,Yeast, Baker's,Yeast, Brewer's,Baker Yeast,S cerevisiae,Baker's Yeasts,Yeast, Baker
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
March 2010, Journal of immunology (Baltimore, Md. : 1950),
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
November 2005, Journal of immunology (Baltimore, Md. : 1950),
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
March 2004, The Journal of biological chemistry,
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
January 1997, Annual review of immunology,
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
November 2010, Experimental eye research,
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
December 2000, Journal of immunology (Baltimore, Md. : 1950),
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
June 1991, Journal of immunology (Baltimore, Md. : 1950),
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
February 2002, The Journal of biological chemistry,
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
January 2012, PloS one,
Carlos Leon, and Devki Nandan, and Martin Lopez, and Alireza Moeenrezakhanlou, and Neil E Reiner
July 2004, Journal of biochemistry,
Copied contents to your clipboard!